Skip to content

XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Coronavirus – COVID-19 Program
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

XORTX Announces Filing of FDA pre-IND Meeting Request Letter

XORTX Announces Filing of FDA pre-IND Meeting Request Letter
XORTX Announces Filing of FDA pre-IND Meeting Request Letter

Press Releases

  • XORTX Welcomes New Member to Board of Directors May 13, 2021
  • XORTX Confirms $1 Million in Warrant Exercise Proceeds March 2, 2021
  • XORTX Participating in WuXI Healthcare Forum March 1, 2021
  • XORTX Closes Over Subscribed Private Placement February 10, 2021
  • XORTX Announces Over Subscribed Private Placement February 8, 2021
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress